Vertex Pharmaceuticals
About
Vertex Pharmaceuticals is a global biotechnology company headquartered on the Seaport waterfront, known for medicines that treat the underlying cause of cystic fibrosis. Its CF drugs, including Trikafta, have changed care for a large share of people with the disease. The company has expanded into other serious illnesses, and with partner CRISPR Therapeutics it developed Casgevy, the first approved CRISPR-based gene-editing therapy, for sickle cell disease and beta thalassemia.
Founded in Cambridge in 1989, Vertex moved its headquarters to two towers at Fan Pier in the Seaport in 2014, making it one of the anchor employers of the neighborhood. In 2025 the FDA approved its non-opioid pain medicine Journavx for acute pain, and the company continues research in areas such as kidney disease, diabetes and pain. The Seaport campus houses offices and laboratories, and the site is a workplace rather than a public-facing business.
What to Know
- Vertex is a publicly traded company listed on the Nasdaq.
- The company is a major employer in the Boston life sciences industry.
- It is listed in the Boston Seaport directory run by WS Development.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.